EUVIMEDSkopri EUVIMED
BeobachtungsstudieOpen access

Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort

D Cecchini, M Brizuela, M S Seleme, M V Mingrone, G Copertari, B Bacelar, R Mauas, E Bottaro, I Cassetti

Revista Española de Quimioterapia · 2025-01-10 · 38 (1) · 40-47

DOI: 10.37201/req/080.2024 ↗

At a glance

Beobachtungsstudie in Revista Española de Quimioterapia, published online on 2024-11-20. Written by D Cecchini and 8 co-authors. Institution: Diego Cecchini, Helios Salud SA, Perú 1511/15, Buenos Aires, C1141ACG, Argentina. dcecchini@heliossalud.com.ar. Major MEDLINE topics: HIV Infections, Emtricitabine, Anti-HIV Agents, Tenofovir. Cited 3 times so far (Crossref). The full text is freely available in PubMed Central.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Introduction

Real-world data on bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) fixed-dose combination from resource-constrained settings like Latin America are limited. Material and methods. We conducted an observational retrospective cohort study of treatment-naive (TN, n=315) and treatment-experienced (TE, n= 2356) people living with HIV prescribed BIC/FTC/TAF in Argentina from 10/2019 to 12/2021, with 24 and 48-week follow-up data analyzed for virological suppression, persistence, safety, and metabolic parameters. Patient-reported outcomes were assessed via across-sectional online survey.

Results

Baseline characteristics: median age 45 years, 72.2% male, 99.6% Hispanic/Latino ethnicity. Treatment per sistence at 48 weeks was 99.3% (TN) and 99.5% (TE). Virological suppression rates (

Subjects

MeSH terms (MEDLINE)

HIV InfectionsEmtricitabineAnti-HIV AgentsTenofovirAdenineHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, 3-RingHumansMaleMiddle AgedRetrospective StudiesFemalePatient Reported Outcome MeasuresArgentinaAdultDrug CombinationsAlanineTreatment OutcomePiperazinesCohort StudiesViral LoadPyridonesAmides

Author keywords

Antiretroviral therapyArgentinaHIVLatin Americabictegravir

Substances

EmtricitabineAnti-HIV AgentsTenofovirDrug CombinationsAdenineAlaninebictegravirPiperazinesHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, 3-Ring

Authors and institutions

  • Diego Cecchini, Helios Salud SA, Perú 1511/15, Buenos Aires, C1141ACG, Argentina. dcecchini@heliossalud.com.ar.

Cite

APA

Cecchini, D., Brizuela, M., Seleme, M. S., Mingrone, M. V., Copertari, G., Bacelar, B., Mauas, R., Bottaro, E., & Cassetti, I. (2025). Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort. Revista Española de Quimioterapia, 38(1), 40-47. https://doi.org/10.37201/req/080.2024

Vancouver

Cecchini D, Brizuela M, Seleme MS, Mingrone MV, Copertari G, Bacelar B, et al. Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort. Revista Española de Quimioterapia. 2025;38(1):40-47. doi:10.37201/req/080.2024

BibTeX
@article{Cecchini2025,
  author = {Cecchini, D and Brizuela, M and Seleme, M S and Mingrone, M V and Copertari, G and Bacelar, B and Mauas, R and Bottaro, E and Cassetti, I},
  title = {Effectiveness, safety, and patient-reported outcomes of treatment with bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination in people living with HIV in Argentina: the BICTARG cohort},
  journal = {Revista Española de Quimioterapia},
  year = {2025},
  volume = {38},
  number = {1},
  pages = {40--47},
  doi = {10.37201/req/080.2024}
}
Start for free →